Navigation Links
Prism Pharmaceuticals Appoints Maurits Geerlings Vice President of Business Development
Date:10/3/2007

KING OF PRUSSIA, Pa., Oct. 3 /PRNewswire/ -- Prism Pharmaceuticals, Inc., a privately-held, specialty pharmaceutical company committed to developing and commercializing acute care cardiovascular products, announced today the appointment of Maurits W. Geerlings, MD, MBA, to the position of Vice President, Business Development.

"I am pleased to welcome Dr. Geerlings to this important business development role at Prism because he brings a tremendous amount of relevant industry experience and relationships to the Company," said Warren Cooper, President and CEO of Prism. "Maurits shares our belief that significant opportunities exist to deliver better solutions to therapeutic challenges in the acute care setting and will further strengthen our focus on market need- based pipeline expansion and partnering."

Dr. Geerlings has more than 15 years of industry experience, including a strong entrepreneurial background and business development expertise spanning cardiology, oncology, and neurology. Prior to joining Prism, Dr. Geerlings served in business development roles at Cephalon, Inc. and Alexion Pharmaceuticals, Inc. Dr. Geerlings was a co-founder of Actinium Pharmaceuticals where he was responsible for fundraising, research & development, government affairs and corporate development. He received his medical degree from The University of Utrecht in the Netherlands and his Masters in Business Administration from The George Washington University in Washington, D.C.

About Prism Pharmaceuticals, Inc.

Prism, founded in September 2004 and based in King of Prussia, Pennsylvania, is a specialty pharmaceutical company committed to developing and commercializing acute care cardiovascular products. For further information, visit http://www.prismpharma.com.


'/>"/>
SOURCE Prism Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... 2016 , ... Research has shown that building shame resilience ... and level of relapse. , At the 2016 iaedp Symposium, the ... the critical tasks of the recovery phase and beyond including relapse prevention and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
(Date:2/5/2016)... City, UT (PRWEB) , ... February 05, 2016 , ... ... Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in ... Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology: